Achieve Life Sciences (ACHV) on Friday filed a shelf registration statement for the potential sale of up to $300 million of its securities from time to time.
The filing covers the sale of common stock, preferred stock, debt securities, warrants, subscription rights and units.
Net proceeds from the sale of securities will be for general corporate purposes, unless otherwise specified in a prospectus supplement.